|Systematic (IUPAC) name|
|Metabolism||Hepatic (mostly via conjugation)|
|Mol. mass||365.49 g/mol|
|(what is this?)|
Pericyazine is a rather sedating and anticholinergic antipsychotic, and despite being classed with the typical antipsychotics, its risk of extrapyramidal side effects is comparatively low. It has a relatively high risk of causing hyperprolactinaemia and a moderate risk of causing weight gain and orthostatic hypotension.
- "NEULACTIL PRODUCT INFORMATION" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 13 September 2011. Retrieved 2 November 2013.
- Pericyazine. Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 23 September 2011. Retrieved 2 November 2013.
- Sivolap IuP, Savchenkov VA (1999). "[The use of neuroleptics in treating opiate dependence]". Zh Nevrol Psikhiatr Im S S Korsakova (in Russian) 99 (6): 29–34. PMID 10441864.
- "Approximate relative frequency (not intensity) of common adverse effects of antipsychotics (Table 8.21) [NB1]". eTherapeutic Guidelines complete. Therapeutic Guidelines Limited. February 2013. Retrieved 2 November 2013.
- Neulactil - Summary of Product Characteristics from the electronic Medicines Compendium
-  from the Therapeutic Goods Administration.
-  from Health Canada.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|